Author: Vivian Xie 22nd May 2026

The American biopharmaceutical industry stands at a critical crossroads. The sector remains responsible for delivering groundbreaking, transformative therapies, but its sustainability and accessibility is being threatened by the escalating cost of drug development. Timelines are stretching beyond a decade, and the average cost of development hit a staggering $2.67 billion per approved drug [1] last year. As such, the imperative for cost optimization has never been more urgent.

For American patients, these development costs translate directly into higher prices, which are straining household budgets in an already precarious economy, forcing impossible treatment decisions, and creating disparities in healthcare access. For biopharma companies, these unsustainable development costs constrain innovation, limit pipeline diversity, and increase financial risk. So how does the industry reimagine these processes without compromising scientific rigor or regulatory standards?

Understanding the Challenge of the Development Cost Crisis 

The rising cost of biopharma development in the US has been driven by several factors, most of which converge in the increased complexity of clinical trials, which require larger patient populations, longer duration, and more extensive data collection than past studies. What’s more, these costs are rising on both sides of the equation, with increased R&D spending leading to fewer assets actually being created later in the pipeline. This raises the minimum risk-adjusted value each program needs to generate to counteract their cost to develop, meaning portfolios with many lower forecast value assets face increasing pressure.

Regulatory requirements have expanded substantially, particularly for novel therapeutic modalities. Biologics, cell therapies, and gene therapies demand specialized manufacturing capabilities, extensive characterization studies, and long-term safety monitoring that was never a concern in the development of traditional small molecule pharmaceuticals. Failure rates compound these cost pressures; only approximately 1 in 10 drug candidates actually reaches approval, [2] which means that successful products need to absorb the development costs of numerous failed programs.

For American patients, these escalating costs manifest as high drug prices that strain affordability. Research from Bentley University [3] demonstrates clear connections between development costs and pricing decisions, highlighting the importance of cost optimization strategies that can ultimately improve drug affordability without compromising innovation. As the research makes clear, policymakers do not need to make a "false choice" between affordability and innovation, and it is indeed possible for the biopharmaceutical industry to simultaneously deliver new drugs to market while ensuring essential medicines are affordable on a nationwide level.

Contract Manufacturing: Strategic Outsourcing for Cost Efficiency 

Contract manufacturing has emerged as one of the most effective strategies for cost optimization at US biopharma companies’ disposal. Rather than investing hundreds of millions in dedicated manufacturing infrastructure that may sit idle between campaigns, companies can leverage contract development and manufacturing organizations (CDMOs) who can provide flexible, scalable production capabilities.

The financial advantages are substantial: the overall CDMO market is expected to grow from $173 billion in 2024 to $323 billion by 2033, [4] a compound annual growth rate (CAGR) of 7.2%. However, demand for biologics CDMO services is growing almost three times higher than demand for pharmaceuticals, and twice as high as demand for pharma CDMO services overall.

Markets and Markets' pharmaceutical contract manufacturing analysis [5] confirms that one of the primary advantages of pharmaceutical contract manufacturing is cost efficiency. As these organizations have their own established production facilities, pharmaceutical companies have no need to invest in their own expensive infrastructure, equipment, and regulatory compliance measures. In 2023, the market was valued at $183.6 billion, projected to reach $200.9 billion by 2024, and expected to hit $319.6 billion by 2029, with an impressive CAGR of 9.7%.

Modern CDMOs offer far more than basic manufacturing services. Leading organizations provide integrated capabilities spanning process development, analytical method development, regulatory support, and commercial-scale production. According to Tablets & Capsules' analysis of CDMO emerging technologies, [6] modern outsourcing relationships have become more strategic and technologically sophisticated, with CDMOs building capability and expertise in continuous manufacturing, automation, AI-driven analytics, and digital process controls.

This value extends beyond cost savings. CDMOs maintain state-of-the-art equipment and specialized expertise across multiple therapeutic modalities, providing access to capabilities that would be prohibitively expensive for individual companies to maintain internally. Especially for early-stage biotech companies, this capital efficiency can mean the difference between advancing promising candidates and abandoning them due to funding constraints.

Clinical Trial Optimization: Smarter Design for Better Outcomes 

Clinical trials represent the main driver of drug development costs, typically consuming 60-70% of total development expenditure. Optimizing trial design offers enormous potential for cost reduction while potentially improving the quality and speed of evidence generation.

One of the most promising approaches is the introduction of adaptive trial designs, which allow ongoing trials to be modified based on accumulating data, enabling more efficient resource allocation and faster decision-making. According to the FDA's September 2025 draft guidance E20 on Adaptive Designs for Clinical Trials, [7] the International Council for Harmonisation (ICH) guidance is intended to provide a transparent and harmonized set of recommendations for clinical trials with an adaptive design, focusing on principles for planning, conduct, analysis, and interpretation.

Decentralized clinical trials (DCTs) have also gained substantial momentum, particularly in the wake of the COVID-19 pandemic. By bringing trial activities to patients rather than mandating site visits, DCTs reduce patient burden, improving retention, and decreasing overall operational costs. According to BCC Research's March 2026 market analysis, [8] the global market for decentralized clinical trials was valued at $8.8 billion in 2024 and is projected to reach $18.8 billion by the end of 2030, a CAGR of 13.7% by the start of the next decade.

Global Market Insights' 2025 DCT market report [9] confirms that “the global decentralized clinical trials market size was valued at $8.6 billion in 2024, expected to grow from $9.7 billion in 2025 to $29.7 billion in 2034, at a CAGR of 13.3%.” The report highlights that cost efficiency and accelerated timelines are major drivers, with DCTs enabling remote data collection, real-time monitoring, and scalable trial execution across diverse geographies.

Real-world evidence (RWE) integration offers additional opportunities for optimization. In December 2025, the FDA announced [10] it would be eliminating a major barrier to the use of RWE in medical device regulatory submissions, by no longer requiring sponsors to provide individually identifiable source data. The FDA also indicated its intention to consider making a similar change for drugs and biologics, perhaps signalling a broader shift in FDA policy.

IQVIA's January 2026 analysis of the FDA's updated RWE guidance [11] expands and clarifies how FDA staff and sponsors may use real-world data to support regulatory decisions, with a key update: the FDA will accept RWE without always requiring submission or availability of identifiable individual participant-level data derived from RWD. This policy shift opens the door for the use of large, de-identified healthcare datasets, such as registries and claims databases.

How Data-Driven Decision Making Improves Efficiency 

Advanced analytics and artificial intelligence have optimized resource allocation and reduced costly failures in the decision making process. The pharmaceutical industry generates enormous volumes of data across discovery, development, and commercialization, yet has historically struggled to extract actionable insights from this wealth of information.

According to Intuition Labs' comprehensive analysis of AI in drug development, [12] the global AI in clinical trials market is expected to grow at a CAGR of 24-28% to reach $8.5 billion by 2030. Pharmaceutical and biotechnology companies constitute over 75% of market share in 2025, with industry analysts projecting that by 2030, AI will be integrated into 60-70% of clinical trials. This will result in dramatically faster timelines and an estimated annual saving of $20-30 billion, through efficiency gains and shorter trial durations.

Blackthorn AI's 2025 market analysis [13] confirms that the pharmaceutical industry is shifting away from traditional, high-cost, low-success drug discovery methods toward artificial intelligence, which is now critical in addressing unmet medical needs by making the development pipeline faster, cheaper, and more precise. The market for AI in drug development is projected to grow from $1.76 billion in 2024 to $13.24 billion by 2035.

Predictive analytics can identify promising drug candidates earlier, reducing investment in compounds which are deemed unlikely to succeed. Intuition Labs reports [14] that Exscientia's pioneering work in AI-driven drug discovery demonstrated an 85% reduction in compounds needed for development, saving enormous time and cost. Insilico Medicine reported using AI to identify a novel drug target and design a lead molecule for idiopathic pulmonary fibrosis, advancing it through preclinical testing to Phase I readiness in under 18 months, at roughly 10% of the cost of traditional programs.

Biomarker-driven development represents another powerful application of data analytics; by identifying biomarkers that predict treatment response, companies can enrich trial populations with patients most likely to benefit, reducing required sample sizes and improving success probability. Global Market Insights' 2025 biomarker discovery outsourcing services market analysis [15] shows the market increased from $10.1 billion in 2023 to $12.4 billion in 2024, with projections reaching $15.1 billion in 2025 and $88.7 billion by 2035, at a CAGR of 19.4%.

Portfolio optimization through data analytics helps companies allocate resources to programs with the highest probability of success and commercial potential. Deloitte's 2025 Life Sciences Executive Outlook [16] notes that several organizations, including J&J, BMS, Roche, and Moderna, have announced pipeline reductions to strategically allocate resources to their most promising prospects, with artificial intelligence investments by biopharma companies over the next five years potentially generating up to 11% in value relative to revenue across functional areas.

 Manufacturing Innovation: Process Efficiency and Quality by Design 

Continuous manufacturing has emerged as a transformative approach for both small molecules and biologics. Unlike traditional batch processing, continuous manufacturing operates as an integrated, ongoing process that reduces equipment footprint, improves process control, and decreases production costs. According to Global Market Insights' continuous manufacturing market analysis, [17] the pursuit of operational efficiency and cost reduction is a major driver of growth. As such, implementing this process has streamlined production measures with fewer interruptions, reducing waste, energy consumption, and labor costs, and translating into significant long-term savings and faster time-to-market for pharmaceutical products.

Evotec's analysis of continuous biomanufacturing for first-in-human supply [18] highlights that one of the most compelling advantages of continuous biomanufacturing is the ability to produce greater quantities of the product in a single run. This is particularly beneficial for supply in early phase clinical trials, which can often be enough to cover subsequent Phase 2a and Phase 2b clinical studies. The financial implications for start-ups in this field are profound, with cost savings from eliminating additional batches potentially amounting to millions of dollars.

Quality by Design (QbD) principles emphasize understanding and controlling manufacturing processes to ensure consistent quality. By identifying critical quality attributes and process parameters during development, QbD approaches reduce costly manufacturing failures and regulatory delays. According to Intuition Labs' 2025 analysis of QbD and PAT in pharma manufacturing, [19] Quality by Design is the cornerstone philosophy for embedding quality upstream. QbD means designing a pharmaceutical product and its manufacturing process with predetermined objectives so that quality is an outcome of process understanding, not just a final inspection.

Pharma Excipients' 2025 article on rethinking pharmaceutical industry QbD [20] notes that these principles can reduce development time by up to 40% by optimizing formulation parameters before full-scale manufacturing. Additionally, the ability to define and control a robust design space has led to fewer batch failures, in some reported cases reducing material wastage by up to 50%.

Explore the Road Ahead for Cost Optimization at CPHI Americas 

The imperative for cost optimization in US biopharma development extends beyond corporate financial performance to encompass drug affordability for American patients. Every dollar saved in development could then be passed on to help improve patient access to life-changing therapies.

ZS Associates' pharmaceutical trends outlook for 2025 [21] confirms that 85% of biopharma executives are planning to invest in data, digital, and AI in R&D for 2025. One top-10 pharma company expects to save roughly $1 billion in drug development costs over five years through these investments.

CPHI Americas provides the premier platform for discovering and implementing cost optimization strategies. The event brings together CDMOs offering flexible manufacturing solutions, technology providers delivering data analytics and trial optimization tools, and industry experts sharing best practices in efficient development. For US biopharma companies committed to sustainable innovation and improved drug affordability, CPHI Americas offers the insights, technologies, and partnerships that transform cost optimization from aspiration to reality.

The future of American biopharmaceutical innovation depends on our collective ability to develop transformative therapies more efficiently. Through leveraging contract manufacturing, optimizing clinical trials, and embracing data-driven decision-making, the industry can remain at the forefront of innovation while improving the overall experience for the all-important end users – the patients themselves.